Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

Description

NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this NOFO encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this NOFO is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

Official source

Eligible beneficiaries

• State governments
• Public housing authorities/Indian housing authorities
• Special district governments
• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• For profit organizations other than small businesses
• County governments
• Small businesses
• Others (see text field entitled "Additional Information on Eligibility" for clarification)
• Native American tribal governments (Federally recognized)
• Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
• Private institutions of higher education
• City or township governments
• Public and State controlled institutions of higher education
• Independent school districts
• Native American tribal organizations (other than Federally recognized tribal governments)